Christopher Marai
Stock Analyst at Nomura
(2.45)
# 2,348
Out of 4,732 analysts
33
Total ratings
51.61%
Success rate
10.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Marai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $360 → $960 | $11.92 | +7,953.69% | 2 | Jun 4, 2020 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $29 → $33 | $36.82 | -10.37% | 2 | May 11, 2020 | |
| SLDB Solid Biosciences | Maintains: Buy | $150 → $90 | $3.27 | +2,652.29% | 5 | May 8, 2020 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Reduce | $74 | $246.27 | -69.95% | 4 | Apr 14, 2020 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $37 → $16 | $5.07 | +215.58% | 2 | Mar 30, 2020 | |
| BIIB Biogen | Maintains: Buy | $320 → $392 | $140.55 | +178.90% | 7 | Feb 7, 2020 | |
| BYSI BeyondSpring | Initiates: Buy | $34 | $1.72 | +1,876.74% | 1 | Jan 10, 2020 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $205 → $230 | $118.00 | +94.92% | 3 | Feb 28, 2019 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $22 → $12 | $13.08 | -8.26% | 3 | Dec 17, 2018 | |
| PRTA Prothena Corporation | Maintains: Buy | $87 → $19 | $13.77 | +37.98% | 2 | Apr 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $43 | $1.48 | +2,805.41% | 2 | Sep 6, 2017 |
Corbus Pharmaceuticals Holdings
Jun 4, 2020
Maintains: Buy
Price Target: $360 → $960
Current: $11.92
Upside: +7,953.69%
Protagonist Therapeutics
May 11, 2020
Maintains: Buy
Price Target: $29 → $33
Current: $36.82
Upside: -10.37%
Solid Biosciences
May 8, 2020
Maintains: Buy
Price Target: $150 → $90
Current: $3.27
Upside: +2,652.29%
Alnylam Pharmaceuticals
Apr 14, 2020
Maintains: Reduce
Price Target: $74
Current: $246.27
Upside: -69.95%
Voyager Therapeutics
Mar 30, 2020
Maintains: Buy
Price Target: $37 → $16
Current: $5.07
Upside: +215.58%
Biogen
Feb 7, 2020
Maintains: Buy
Price Target: $320 → $392
Current: $140.55
Upside: +178.90%
BeyondSpring
Jan 10, 2020
Initiates: Buy
Price Target: $34
Current: $1.72
Upside: +1,876.74%
Sarepta Therapeutics
Feb 28, 2019
Maintains: Buy
Price Target: $205 → $230
Current: $118.00
Upside: +94.92%
Syndax Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: $22 → $12
Current: $13.08
Upside: -8.26%
Prothena Corporation
Apr 24, 2018
Maintains: Buy
Price Target: $87 → $19
Current: $13.77
Upside: +37.98%
Sep 6, 2017
Maintains: Buy
Price Target: $49 → $43
Current: $1.48
Upside: +2,805.41%